| Intellia Therapeutics is a genome editing company focused on developing therapeutics utilizing a biological tool known as Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9). This is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. Co. utilizes its CRISPR/Cas9 platform across two areas: in vivo and ex vivo therapies. Co.'s in vivo candidate, NTLA-2001 for the treatment of transthyretin amyloidosis is the delivered CRISPR/Cas9-based therapy to enter clinical evaluation. Co.'s ex vivo applications to address immuno-oncology and autoimmune diseases. We show 24 historical shares outstanding datapoints in our NTLA shares outstanding history coverage, used to compute NTLA market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NTLA market cap history over the course of time is important for investors
interested in comparing NTLA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NTLA versus a peer is one thing; comparing
NTLA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NTLA can fluctuate over the course of history.
With this page we aim to empower investors researching NTLA by allowing them to research the NTLA market cap history.